Following a major dive in share price yesterday, shares of Uniqure NV (NASDAQ:QURE) seem to be on the rebound in afternoon trading today. After opening trading yesterday at $17.56, the stock dropped to close the day at $15.97. Today, the story was quite a bit different, as shares opened the day trading at $16.30 and have continued to gain throughout the day.
With a market cap of just $48.74 million and having fallen from a 52-week high of over $36, investors may finally be looking at Uniqure NV (NASDAQ:QURE) as a value play. The stock is up 11.77% or $1.88 following the news, hitting $17.85 per share. About 318,324 shares traded hands. QURE has declined 43.55% since May 12, 2015 and is downtrending. It has underperformed the S&P500 by 39.87%.
From a total of 8 analysts covering uniQure N.V. (NASDAQ:QURE) stock, 8 rate it a “Buy”, 0 a “Sell”, and 0 a “Hold”. This means that 100% of the ratings are positive. The highest target price is $60 while the lowest target price is $33. The mean of all analyst targets is $44 which is 146.50% above today’s ($17.85) stock price. uniQure N.V. was the topic of 15 analyst reports since August 7, 2015 according to the firm StockzIntelligence Inc. Janney Capital initiated shares on December 1 with a “Buy” rating. Piper Jaffray maintained shares with a”Overweight” rating and a $40 target share price in their report from an August 28. Roth Capital reinitiated QURE stock in a recent report from November 30 with a “Buy” rating. Finally, Chardan Capital Markets maintained the stock with a “Buy” rating in a report they issued on an October 1.
Uniqure NV is a pharmaceutical company based in the Netherlands. The company has a market cap of $48.74 million. It is primarily engaged in the field of gene therapy for orphan diseases. It currently has negative earnings. The Firm is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.